| dc.contributor.author | Andreania, Julien et al. | |
| dc.date.accessioned | 2020-04-02T21:25:08Z | |
| dc.date.available | 2020-04-02T21:25:08Z | |
| dc.date.issued | 2020-03 | |
| dc.identifier.uri | https://www.mediterranee-infection.com/wp-content/uploads/2020/03/La-Scola-et-al-V1.pdf | en_US |
| dc.identifier.uri | https://hdl.handle.net/20.500.12663/923 | |
| dc.description.abstract | Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term strategy to treat millions of infected patients at low costs. Hydroxychloroquine showed an antiviral effect in vitro. In vivo it also showed efficacy, especially when combined with azithromycin in a preliminary clinical trial. Here we demonstrate that the combination of hydroxychloroquine and azithromycin has a synergistic effect in vitro on SARS-CoV-2 at concentrations compatible with that obtained in human lung. | en_US |
| dc.language | English | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | SARS-CoV | en_US |
| dc.subject | Hydroxychloroquine | en_US |
| dc.title | In vitro testing of Hydroxychloroquine and Azithromycin on SARS-CoV-2 shows synergistic effect | en_US |
| eihealth.country | Others | en_US |
| eihealth.category | Candidate therapeutics RD | en_US |
| eihealth.type | Other publications | en_US |
| eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
